专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2003101485A1 CD16A BINDING PROTEINS AND USE FOR THE TREATMENT OF IMMUNE DISORDERS 审中-公开
标题翻译： CD16A结合蛋白，用于治疗免疫缺陷病毒
公开(公告)号：WO2003101485A1
公开(公告)日：2003-12-11
申请号：PCT/US2003/017111
申请日：2003-05-29
申请人： MACROGENICS, INC. , JOHNSON, Leslie, S. , HUANG, Ling , LI, Hua , TUAILLON, Nadine
发明人： JOHNSON, Leslie, S. , HUANG, Ling , LI, Hua , TUAILLON, Nadine
IPC分类号： A61K39/395
CPC分类号： C07K16/283 , A61K2039/505 , C07K2317/24 , C07K2317/41 , C07K2317/732
摘要： CD16A binding proteins useful for the reduction of a deleterious immune response are described. In one aspect, humanized anti-CD16A antibodies, optionally lacking effector function, are used for treatment of immune disorders such as idiopathic thrombocytopenic purpura and autoimmune hemolytic anemia.
摘要翻译：描述了可用于减少有害免疫反应的CD16A结合蛋白。一方面，任选缺乏效应子功能的人源化抗CD16A抗体用于治疗免疫疾病，例如特发性血小板减少性紫癜和自身免疫性溶血性贫血。

2. 发明申请

WO2004062619A2 SOLUBLE FcγR FUSION PROTEINS AND METHODS OF USE THEREOF 审中-公开
标题翻译：可溶性FcγAM融合蛋白及其使用方法
公开(公告)号：WO2004062619A2
公开(公告)日：2004-07-29
申请号：PCT/US2004/000725
申请日：2004-01-13
申请人： MACROGENICS, INC. , JOHNSON, Leslie, S. , LI, Hua , TUAILLON, Nadine
发明人： JOHNSON, Leslie, S. , LI, Hua , TUAILLON, Nadine
IPC分类号： A61K
CPC分类号： C07K16/283 , A61K39/39541 , A61K2039/505 , C07K2317/41 , C07K2317/52 , C07K2317/71 , C07K2319/30 , C07K2319/32 , A61K2300/00
摘要： The present invention relates to molecules, preferably soluble (i.e., not membrane bound) polypeptides, most preferably soluble fusion polypeptides comprising the extracellular soluble regions of an FcγR, derivatives and analogs thereof, and nucleic acids encoding same. Molecules of the invention are particularly useful for the treatment, management, or prevention of, or amelioration of one or more symptoms of, an autoimmune disease, especially for ameliorating serum platelet deficiency associated with immune thrombocytopenic purpura. The invention provides methods and compositions for enhancing the therapeutic efficacy of standard, current or experimental therapies for an autoimmune disease by administering a molecule of the invention.
摘要翻译：本发明涉及分子，优选可溶性（即不是膜结合的）多肽，最优选包含FcγR的细胞外可溶性区域的可溶性融合多肽，其衍生物和类似物，以及编码它们的核酸。本发明的分子特别可用于治疗，治疗或预防或改善自身免疫疾病的一种或多种症状，特别是用于改善与免疫性血小板减少性紫癜相关的血小板缺乏症。本发明提供了通过施用本发明的分子来增强用于自身免疫疾病的标准，当前或实验疗法的治疗功效的方法和组合物。

3. 发明申请

WO2008118324A3 COMPOSITION AND METHOD OF TREATING CANCER WITH AN ANTI-UROPLAKIN IB ANTIBODY 审中-公开
标题翻译：抗UROPLAKIN抗体治疗癌症的组合物和方法
公开(公告)号：WO2008118324A3
公开(公告)日：2008-10-02
申请号：PCT/US2008/003635
申请日：2008-03-20
申请人： MACROGENICS, INC. , FERGUSON, Stacy , KOENIG, Scott , TUAILLON, Nadine , JOHNSON, Leslie, S. , HUANG, Ling , RANKIN, Christopher
发明人： FERGUSON, Stacy , KOENIG, Scott , TUAILLON, Nadine , JOHNSON, Leslie, S. , HUANG, Ling , RANKIN, Christopher
IPC分类号： C07K16/28
摘要： This invention provides antibodies that specifically recognize and bind to UPK-Ib. Also included are diagnostic and therapeutic assays directed to diseases associated with unregulated levels of UPK-Ib using said antibodies. The antibodies and derivatives thereof can also be useful in the diagnisic and/or treatment of cancer associated with abnormal expression of UPK-Ib.
摘要翻译：本发明提供了特异性识别并结合UPK-1b的抗体。还包括使用所述抗体针对与未调节水平的UPK-Ib相关的疾病的诊断和治疗测定。所述抗体及其衍生物还可用于诊断和/或治疗与UPK-Ib异常表达相关的癌症。

4. 发明申请

WO2010027797A1 T-CELL RECEPTOR ANTIBODIES AND METHODS OF USE THEREOF 审中-公开
标题翻译： T细胞受体抗体及其使用方法
公开(公告)号：WO2010027797A1
公开(公告)日：2010-03-11
申请号：PCT/US2009/054911
申请日：2009-08-25
申请人： MACROGENICS INC. , BONVINI, Ezio , JOHNSON, Leslie, S. , TUAILLON, Nadine , HUANG, Ling
发明人： BONVINI, Ezio , JOHNSON, Leslie, S. , TUAILLON, Nadine , HUANG, Ling
IPC分类号： C07K16/28 , A61K39/395
CPC分类号： C07K16/2809 , A61K2039/505 , C07K2317/52 , C07K2317/56 , C07K2317/71
摘要： The present invention is directed to the production and use of monoclonal antibodies, or antigen binding fragments thereof, that specifically bind the T cell antigen receptor (TCR) and their use for immunomodulation. In preferred embodiments, the antibody or antigen binding fragment of the invention specifically binds the constant region of the alpha chain of the TCR, or otherwise specifically binds the alpha chain regardless of TCR clonal origin (i.e., is pan specific for TCR). The antibodies of the invention may be used, for example, in immunosuppressive therapies for transplant maintenance and the treatment of autoimmune diseases, and/or as targeting molecules for use in the treatment of T-cell malignancies.
摘要翻译：本发明涉及特异性结合T细胞抗原受体（TCR）及其免疫调节用途的单克隆抗体或其抗原结合片段的生产和使用。在优选的实施方案中，本发明的抗体或抗原结合片段特异性结合TCR的α链的恒定区，或以其他方式特异性结合α链，而不管TCR克隆来源（即TCR的泛特异性）。本发明的抗体可用于例如用于移植维持和治疗自身免疫性疾病的免疫抑制疗法和/或用作治疗T细胞恶性肿瘤的靶向分子。

5. 发明申请

WO2009123894A3 HER2/NEU-SPECIFIC ANTIBODIES AND METHODS OF USING SAME 审中-公开
公开(公告)号：WO2009123894A3
公开(公告)日：2009-10-08
申请号：PCT/US2009/038201
申请日：2009-03-25
申请人： MACROGENICS, INC. , JOHNSON, Leslie, S. , HUANG, Ling , TUAILLON, Nadine , BONVINI, Ezio
发明人： JOHNSON, Leslie, S. , HUANG, Ling , TUAILLON, Nadine , BONVINI, Ezio
IPC分类号： A61K39/00 , C12P21/08
摘要： This invention relates to antibodies that specifically bind HER2/neu, and particularly chimeric 4D5 antibodies to HER2/neu, which have reduced glycosylation as compared to known 4D5 antibodies. The invention also relates to methods of using the 4D5 antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such as cancer, autoimmune diseases, inflammatory disorders, and infectious disease.

6. 发明申请

WO2007009065A2 METHODS OF TREATING AUTOIMMUNE DISEASE USING HUMANIZED ANTI-CD16A ANTIBODIES 审中-公开
标题翻译：使用人类抗CD16A抗体治疗自身免疫疾病的方法
公开(公告)号：WO2007009065A2
公开(公告)日：2007-01-18
申请号：PCT/US2006/027387
申请日：2006-07-11
申请人： MACROGENICS, INC. , TUAILLON, Nadine , JOHNSON, Leslie, S. , BONVINI, Ezio , STEIN, Kathryn, E.
发明人： TUAILLON, Nadine , JOHNSON, Leslie, S. , BONVINI, Ezio , STEIN, Kathryn, E.
IPC分类号： A61K39/395
CPC分类号： C07K16/283 , A61K2039/505 , C07K2317/24 , C07K2317/41 , C07K2317/52 , C07K2317/565 , C07K2317/732 , C07K2317/76
摘要： CD16A binding proteins useful for the reduction of a deleterious immune response are described. In one aspect, humanized anti-CD16A antibodies, optionally lacking effector function, are used for treatment of immune disorders such as idiopathic thrombocytopenic purpura and autoimmune hemolytic anemia.
摘要翻译：描述了可用于减少有害免疫反应的CD16A结合蛋白。一方面，任选缺乏效应子功能的人源化抗CD16A抗体用于治疗免疫疾病，例如特发性血小板减少性紫癜和自身免疫性溶血性贫血。

7. 发明申请

WO2010080538A1 COVALENT DIABODIES AND USES THEREOF 审中-公开
标题翻译：同性双胞胎及其用途
公开(公告)号：WO2010080538A1
公开(公告)日：2010-07-15
申请号：PCT/US2009/068577
申请日：2009-12-17
申请人： MACROGENICS, INC. , JOHNSON, Leslie, S. , HUANG, Ling
发明人： JOHNSON, Leslie, S. , HUANG, Ling
IPC分类号： A61K39/00
CPC分类号： C07K16/283 , A61K2039/505 , C07K16/2803 , C07K16/2809 , C07K16/32 , C07K16/44 , C07K2317/34 , C07K2317/52 , C07K2317/56 , C07K2317/626 , C07K2317/64 , C07K2317/73 , C07K2317/92 , C07K2319/00
摘要： The present invention is directed to diabody molecules and uses thereof in the treatment of a variety of diseases and disorders, including immunological disorders, infectious disease, intoxication and cancers. The diabody molecules of the invention comprise two polypeptide chains that associate to form at least two epitope binding sites, which may recognize the same or different epitopes on the same or differing antigens. Additionally, the antigens may be from the same or different molecules. The individual polypeptide chains of the diabody molecule may be covalently bound through non-peptide bond covalent bonds, such as, but not limited to, disulfide bonding of cysteine residues located within each polypeptide chain. In particular embodiments, the diabody molecules of the present invention further comprise an Fc region, which allows antibody- like functionality to engineered into the molecule.
摘要翻译：本发明涉及双抗体分子及其在治疗各种疾病和病症（包括免疫学疾病，感染性疾病，中毒和癌症）中的用途。本发明的双抗体分子包含两个缔合以形成至少两个表位结合位点的多肽链，其可识别相同或不同抗原上相同或不同的表位。另外，抗原可以来自相同或不同的分子。双抗体分子的单个多肽链可以通过非肽键共价键共价结合，例如但不限于位于每个多肽链内的半胱氨酸残基的二硫键。在具体实施方案中，本发明的双抗体分子还包含Fc区，其允许类似抗体的功能改造成分子。

8. 发明申请

WO2005110474A2 HUMANIZED FcγRIIB SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF 审中-公开
标题翻译：人类FcγRIIB特异性抗体及其使用方法
公开(公告)号：WO2005110474A2
公开(公告)日：2005-11-24
申请号：PCT/US2005/016260
申请日：2005-05-10
申请人： MACROGENICS, INC. , JOHNSON, Leslie, S. , HUANG, Ling
发明人： JOHNSON, Leslie, S. , HUANG, Ling
IPC分类号： A61K39/395
CPC分类号： C07K16/283 , A61K2039/505 , C07K2317/24 , C07K2317/34
摘要： The present invention relates to humanized FcγRIIB antibodies, fragments, and variants thereof that bind human FcγRIIB with a greater affinity than said antibody binds FcγRIIA. The invention encompasses the use of the humanized antibodies of the invention for the treatment of any disease related to loss of balance of Fc receptor mediated signaling, such as cancer, autoimmune and inflammatory disease. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the humanized antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing the efficacy of a vaccine composition by administering the humanized antibodies of the invention. The invention encompasses methods for treating an autoimmune disease and methods for elimination of cancer cells that express FcγRIIB.
摘要翻译：本发明涉及以与抗体结合FcγRIIA更大的亲和力结合人FcγRIIB的人源化FcγRIIB抗体，其片段和变体。本发明包括本发明的人源化抗体用于治疗与Fc受体介导的信号传导的平衡失去相关的任何疾病（例如癌症，自身免疫性和炎性疾病）的用途。本发明提供了通过施用本发明的人源化抗体来增强治疗性抗体的治疗效果以增强治疗性抗体的效应子功能的方法。本发明还提供了通过施用本发明的人源化抗体来增强疫苗组合物的功效的方法。本发明包括治疗自身免疫疾病的方法和用于消除表达FcγRIIB的癌细胞的方法。

9. 发明申请

WO2012162067A3 CD3-BINDING MOLECULES CAPABLE OF BINDING TO HUMAN AND NON-HUMAN CD3 审中-公开
公开(公告)号：WO2012162067A3
公开(公告)日：2012-11-29
申请号：PCT/US2012/038219
申请日：2012-05-16
申请人： MACROGENICS, INC. , HUANG, Ling , JOHNSON, Leslie, S.
发明人： HUANG, Ling , JOHNSON, Leslie, S.
IPC分类号： C07K16/00
摘要： CD3-binding molecules capable of binding to human and non-human CD3, and in particular to such molecules that are cross-reactive with CD3 of a non-human mammal (e.g., a cynomolgus monkey) are presented. Uses of such antibodies and antigen-binding fragments in the treatment of cancer, autoimmune and/or inflammatory diseases and other conditions are presented.

10. 发明申请

WO2006031825A2 HUMANIZED ANTIBODIES AGAINST WEST NILE VIRUS AND THERAPEUTIC AND PROPHYLACTIC USES THEREOF 审中-公开
标题翻译：针对西尼尔病毒的人源化抗体及其治疗和预防用途
公开(公告)号：WO2006031825A2
公开(公告)日：2006-03-23
申请号：PCT/US2005/032587
申请日：2005-09-13
申请人： MACROGENICS, INC. , JOHNSON, Leslie, S. , HUANG, Ling
发明人： JOHNSON, Leslie, S. , HUANG, Ling
IPC分类号： A61K39/42 , C07K16/08
CPC分类号： C07K16/1081 , A61K2039/505 , C07K2317/24 , C07K2317/565 , C07K2317/567 , G01N33/56983 , G01N2333/18 , G01N2469/20 , Y02A50/386 , Y02A50/388 , Y02A50/394 , Y02A50/396 , Y02A50/53 , Y02A50/60
摘要： The present invention relates to compositions comprising humanized antibodies or fragments thereof that immunospecifically bind to one or more antigens of a flavivirus, particularly of West Nile Virus (WNV) and methods for preventing, treating or ameliorating symptoms associated with a flavivirus, particularly of West Nile Virus (WNV) infection utilizing said compositions. In particular, the present invention relates to methods for preventing, treating or ameliorating to a human subject an effective amount of one or more humanized antibodies or fragments thereof that immunospecifically bind to a WNV antigen. The present invention also relates to detectable or diagnostic compositions comprising humanized antibodies or fragments thereof that immunospecifically bind to a WNV antigen and methods for detecting or diagnosing WNV infection utilizing said compositions.
摘要翻译：本发明涉及包含免疫特异性结合黄病毒特别是西尼罗河病毒（WNV）的一种或多种抗原的人源化抗体或其片段的组合物，以及预防，治疗或改善相关症状的方法与利用所述组合物的黄病毒，特别是西尼罗病毒（WNV）感染。特别地，本发明涉及预防，治疗或改善人类受试者有效量的一种或多种免疫特异性结合WNV抗原的人源化抗体或其片段的方法。本发明还涉及包含免疫特异性结合WNV抗原的人源化抗体或其片段的可检测或诊断组合物，以及利用所述组合物检测或诊断WNV感染的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式